Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages

Mélanie Tichet(Inserm), Douglas Hanahan(Ludwig Cancer Research)
Immunity
January 1, 2023
Cited by 127


Related Papers